SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is under pressure amid staggered IPO lockup expirations and a broader AI and semiconductor selloff. Bears point to valuation, growth and customer-concentration concerns, while bullish traders view the decline as oversold and are buying the weakness.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Attention is focused on Deckers upcoming earnings report, with traders weighing HOKA and UGG demand against tariff- and freight-related margin pressure and signs of slower growth. Some are optimistic about the recent rebound and potential buybacks, while others are cautious about the outlook; speculation about a tariff refund remains unconfirmed.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is drawing attention amid a sharp AI-linked semiconductor selloff, with traders citing inflation worries and doubts about the durability of AI investment. The steep decline has prompted debate between dip buyers who view the shares as oversold and bears expecting further weakness.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, amplified by its 3x leverage, as traders debate AI-investment and valuation concerns, Chinese competition, and persistent market pressure. The community is split between calling the extended slide an oversold buying opportunity and warning that further declines may follow, with volatile rebound attempts adding to the uncertainty.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is drawing attention amid a sharp South Korean equity selloff led by chip stocks, with traders linking the weakness to AI-spending concerns, rising yields and foreign selling. Because the ETF delivers 3x daily exposure, its swings are amplified; traders are divided between buying an oversold rebound and warning that further selling and leverage decay could deepen losses.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp tech-led selloff was followed by a futures rebound ahead of major technology earnings. Traders are split on whether the bounce marks dip-buying and short covering or is a bull trap before further declines, with AI-sector worries and the Black Monday anniversary adding to the debate.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA is drawing attention as traders weigh the Dows relative resilience and rotation into blue chips against tech weakness, with hot inflation data and rising yields fueling rate-hike concerns. The community is split between viewing the pullback as sector rotation ahead of earnings and warning of a broader correction, with Black Monday comparisons adding to the anxiety.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

A sharp AMP price and volume surge has driven attention, with traders debating whether it marks a sustained breakout or another short-lived pump-and-dump. Some link the move speculatively to Flexa/AMP payment adoption, ANVL developments, or a possible listing, but the messages do not establish a confirmed new catalyst.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to rising crude prices and fears that reported tanker attacks and Middle East tensions could disrupt oil supplies, alongside strikes on energy infrastructure tied to the Russia-Ukraine conflict. Bulls see a worsening supply squeeze, while bears argue the rally reflects a temporary war premium that could unwind if diplomacy or additional supply eases concerns.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Traders are focused on an anticipated Pyth Connect business update and teased announcement, with speculation about what it could mean for PYTH. Bullish posts point to Pyths institutional market-data adoption and revenue-funded token accumulation, while others remain cautious about token unlocks and weak price performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

 Stock futures are are flat and Treasuries slipped while oil stumbled heading into today's PCE report and NVDA earnings. As of 8:00am ET, S&P Futures are unchanged and Nasdaq futures drop 0.2% as?NVDA and MRVL both rise 0.2% with...

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.

SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?

Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.

Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today

SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?

SYRE and Spyre Ride New IBD Trends in Biotech Drug Design

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$79.90
Prev Close	$80.10
Open	$80.21
Dividend Yield	0.00%
50-Day Moving Average	$92.31
Beta	1.71
Avg. Volume	1.28M
PE Ratio	-36.65

52-Week High	$110.18
52-Week Low	$21.15
Market Capitalization	$7.37B
EPS (Annual)	-$1.98
Price to Book	7.37
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SYRE Fundamentals